

Docket No.: 062386-0043



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	Customer Number: 20277
Wayne D. COMPER	:	Confirmation Number: 6164
Application No.: 10/721,351	:	Group Art Unit: 1648
Filed: November 26, 2003	:	Examiner: Stacy Brown Chen
For: METHOD FOR KIDNEY DISEASE TREATMENT BY DRUG INTERVENTION	:	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached form PTO-1449. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.


Each reference was first cited in a U.S. office action and its relevance is discussed therein.

10/721,351

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

McDERMOTT WILL & EMERY LLP



Judith L. Toffenetti
Registration No. 39,048

600 13th Street, N.W.
Washington, DC 20005-3096
Phone: 202.756.8000 JLT:jwp
Facsimile: 202.756.8087
Date: May 23, 2007

**Please recognize our Customer No. 20277
as our correspondence address.**



SHEET 1 OF 1

INFORMATION DISCLOSURE
CITATION IN AN
APPLICATION

(PTO-1449)

ATTY. DOCKET NO.
062386-0043SERIAL NO.
10/721,351APPLICANT
Wayne D. COMPERFILING DATE
November 26, 2003GROUP
1648

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 6,447,989	09-10-2002	Comper	
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number 4 - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		SVIRIDOV, D., et al., "Coelution of Other Proteins with Albumin during Size-Exclusion HPLC: Implications for Analysis of Urinary Albumin", Clinical Chemistry, 2006, P. 389-397, Vol. 52, Issue 3, American Association for Clinical Chemistry, USA.
		CLAVANT, S. P., et al., "The analysis and characterization of immuno-unreactive urinary albumin in healthy volunteers", Clinical Biochemistry, 2006, Pages 143-151, Volume 39, Elsevier.
		YAGAME, M., et al., "Urinary Albumin Fragments as a New Clinical Parameter for the Early Detection of Diabetic Nephropathy", Internal Medicine, June 1995, Pages 463-468, Volume 34, Issue 6.
		BURNE, M. J., et al., "Alterations in renal degradation of albumin in early experimental diabetes in the rat: a new factor in the mechanism of albuminuria", Clinical Science, 1998, Pages 67-72, Volume 95, The Biochemical Society and the Medical Research Society.
		OHSAWA, S., "Urinary Proteins Assay and Standardization", Japanese J. Clinical Pathology, 1998, Pages 36-42, Volume 107.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.